{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:45:36Z","timestamp":1787222736773,"version":"build-2736575974"},"reference-count":40,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.3892\/or.2013.2666","type":"journal-article","created":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T06:28:55Z","timestamp":1375943335000},"page":"1575-1580","source":"Crossref","is-referenced-by-count":16,"title":["Plasma osteopontin concentrations in patients with cutaneous melanoma"],"prefix":"10.3892","volume":"30","author":[{"given":"A.","family":"FILIA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"ELLIOTT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"WIND","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"FIELD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"DAVIES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"KUKALIZCH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"RANDERSON-MOOR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"HARLAND","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.T.","family":"BISHOP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.E.","family":"BANKS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"NEWTON-BISHOP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2013,8,8]]},"reference":[{"issue":"Suppl 6","key":"key20180107223404_b1-or-30-04-1575","doi-asserted-by":"crossref","first-page":"vi8","DOI":"10.1093\/annonc\/mdp251","article-title":"Biomarkers in melanoma","volume":"20","author":"Gogas","year":"2009","journal-title":"Ann Oncol"},{"key":"key20180107223404_b2-or-30-04-1575","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180107223404_b3-or-30-04-1575","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/CMR.0b013e32831bc78c","article-title":"Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma","volume":"19","author":"Hofmann","year":"2009","journal-title":"Melanoma Res"},{"key":"key20180107223404_b4-or-30-04-1575","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1158\/1078-0432.CCR-09-0886","article-title":"Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B","volume":"15","author":"Paschen","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180107223404_b5-or-30-04-1575","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/sj.bjc.6601839","article-title":"Role of osteopontin in tumour progression","volume":"90","author":"Rittling","year":"2004","journal-title":"Br J Cancer"},{"key":"key20180107223404_b6-or-30-04-1575","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/15216540500159424","article-title":"Osteopontin: it\u2019s role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression","volume":"57","author":"Das","year":"2005","journal-title":"IUBMB Life"},{"key":"key20180107223404_b7-or-30-04-1575","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/carcin\/bgl016","article-title":"Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN","volume":"27","author":"Packer","year":"2006","journal-title":"Carcinogenesis"},{"key":"key20180107223404_b8-or-30-04-1575","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tcb.2005.12.005","article-title":"Osteopontin: role in cell signaling and cancer progression","volume":"16","author":"Rangaswami","year":"2006","journal-title":"Trends Cell Biol"},{"key":"key20180107223404_b9-or-30-04-1575","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrc2345","article-title":"Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer","volume":"8","author":"Bellahcene","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"key20180107223404_b10-or-30-04-1575","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.4161\/cbt.4.9.2165","article-title":"Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi\/melanoma in situ and advanced-stage melanomas","volume":"4","author":"Smith","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"key20180107223404_b11-or-30-04-1575","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cncr.23147","article-title":"Osteopontin as a molecular prognostic marker for melanoma","volume":"112","author":"Rangel","year":"2008","journal-title":"Cancer"},{"key":"key20180107223404_b12-or-30-04-1575","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/j.0022-202X.2005.23680.x","article-title":"Osteopontin expression correlates with melanoma invasion","volume":"124","author":"Zhou","year":"2005","journal-title":"J Invest Dermatol"},{"key":"key20180107223404_b13-or-30-04-1575","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1468-3083.2011.04210.x","article-title":"Osteopontin expression in plasma of melanoma patients and in melanocytic tumours","volume":"26","author":"Maier","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20180107223404_b14-or-30-04-1575","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1158\/1078-0432.CCR-09-1631","article-title":"Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival","volume":"15","author":"Conway","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180107223404_b15-or-30-04-1575","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1158\/1078-0432.CCR-06-1820","article-title":"Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues","volume":"13","author":"Jaeger","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20180107223404_b16-or-30-04-1575","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2353\/ajpath.2010.090748","article-title":"Metastatic outgrowth encompasses COL-I, FN1, and POSTN up-regulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth","volume":"177","author":"Soikkeli","year":"2010","journal-title":"Am J Pathol"},{"key":"key20180107223404_b17-or-30-04-1575","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1158\/1078-0432.CCR-09-1777","article-title":"A multimarker prognostic assay for primary cutaneous melanoma","volume":"15","author":"Kashani-Sabet","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180107223404_b18-or-30-04-1575","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1158\/0008-5472.CAN-06-3481","article-title":"A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis","volume":"67","author":"Alonso","year":"2007","journal-title":"Cancer Res"},{"key":"key20180107223404_b19-or-30-04-1575","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/1055-9965.EPI-06-1008","article-title":"The role of osteopontin in tumor progression and metastasis in breast cancer","volume":"16","author":"Rodrigues","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20180107223404_b20-or-30-04-1575","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s12032-011-0012-z","article-title":"Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosis","volume":"29","author":"Li","year":"2012","journal-title":"Med Oncol"},{"key":"key20180107223404_b21-or-30-04-1575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00432-009-0629-x","article-title":"The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma","volume":"136","author":"Sun","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20180107223404_b22-or-30-04-1575","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/JTO.0b013e3181ae2844","article-title":"Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004","volume":"4","author":"Isa","year":"2009","journal-title":"J Thorac Oncol"},{"key":"key20180107223404_b23-or-30-04-1575","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1200\/JCO.2009.25.5711","article-title":"Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer","volume":"28","author":"Blasberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180107223404_b24-or-30-04-1575","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1200\/JCO.2009.26.9944","article-title":"Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma","volume":"28","author":"Wheatley-Price","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180107223404_b25-or-30-04-1575","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ajo.2006.11.040","article-title":"Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study","volume":"143","author":"Reiniger","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"key20180107223404_b26-or-30-04-1575","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000206139","article-title":"Osteopontin and \u2018melanoma inhibitory activity\u2019: comparison of two serological tumor markers in metastatic uveal melanoma patients","volume":"223","author":"Haritoglou","year":"2009","journal-title":"Ophthalmologica"},{"key":"key20180107223404_b27-or-30-04-1575","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1167\/iovs.05-0422","article-title":"Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study","volume":"47","author":"Kadkol","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20180107223404_b28-or-30-04-1575","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1158\/1078-0432.CCR-10-2402","article-title":"Plasma markers for identifying patients with metastatic melanoma","volume":"17","author":"Kluger","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180107223404_b29-or-30-04-1575","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1200\/JCO.2009.22.1135","article-title":"Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma","volume":"27","author":"Newton-Bishop","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180107223404_b30-or-30-04-1575","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1258\/acb.2010.010240","article-title":"Measuring carbonic anhydrase IX as a hypoxia biomarker: differences in concentrations in serum and plasma using a commercial enzyme-linked immunosorbent assay due to influences of metal ions","volume":"48","author":"Wind","year":"2011","journal-title":"Ann Clin Biochem"},{"key":"key20180107223404_b31-or-30-04-1575","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/bjc.2012.360","article-title":"Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma","volume":"107","author":"Sim","year":"2012","journal-title":"Br J Cancer"},{"key":"key20180107223404_b32-or-30-04-1575","volume-title":"StataCorp: Stata Statistical Software: Release 10","year":"2007"},{"key":"key20180107223404_b33-or-30-04-1575","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/00365510701432509","article-title":"Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein","volume":"67","author":"Sennels","year":"2007","journal-title":"Scand J Clin Lab Invest"},{"key":"key20180107223404_b34-or-30-04-1575","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/107327480501200403","article-title":"Cutaneous melanoma: prognostic factors","volume":"12","author":"Homsi","year":"2005","journal-title":"Cancer Control"},{"key":"key20180107223404_b35-or-30-04-1575","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00000658-198808000-00004","article-title":"Lethal \u2018thin\u2019 malignant melanoma. Identifying patients at risk","volume":"208","author":"Slingluff","year":"1988","journal-title":"Ann Surg"},{"key":"key20180107223404_b36-or-30-04-1575","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"key20180107223404_b37-or-30-04-1575","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"key20180107223404_b38-or-30-04-1575","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/ncponc1187","article-title":"Strategies for discovering novel cancer biomarkers through utilization of emerging technologies","volume":"5","author":"Kulasingam","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"key20180107223404_b39-or-30-04-1575","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00403-006-0726-5","article-title":"Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies","volume":"298","author":"Utikal","year":"2007","journal-title":"Arch Dermatol Res"},{"key":"key20180107223404_b40-or-30-04-1575","first-page":"345","article-title":"The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1)","volume":"31","author":"Barak","year":"2011","journal-title":"Anticancer Res"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2013.2666\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T22:43:12Z","timestamp":1515364992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2013.2666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,8]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,8,8]]},"published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.3892\/or.2013.2666"],"URL":"https:\/\/doi.org\/10.3892\/or.2013.2666","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,8]]}}}